ClearB Therapeutics
Blood & Organ Banks · Massachusetts, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
530 Virginia Rd Ste 300, Concord, Massac...Website
www.clearbtherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 2
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
2
2
2
2
About ClearB Therapeutics
ClearB Therapeutics is focused on developing a therapeutic vaccine aimed at redirecting the immune system of patients to achieve a functional cure for hepatitis B. The company addresses the unmet medical need for effective treatments in this area. Their innovative approach is currently being evaluated through clinical trials. ClearB Therapeutics targets patients suffering from hepatitis B who are seeking new therapeutic options.Explore more
ClearB Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is ClearB Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if ClearB Therapeutics is spiking on competitors!
Click to see if ClearB Therapeutics had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at ClearB Therapeutics
Check if ClearB Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when ClearB Therapeutics launches new products
Funding: Get notified immidiatlly once ClearB Therapeutics has new funding data
Website visits: Recent activity has been detected on your website
ClearB Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on ClearB Therapeutics recently announced quarterly report
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to ClearB Therapeutics
Compare insights from companies similar to ClearB Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
ClearB Therapeutics is experiencing very low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
ClearB Therapeutics is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about ClearB Therapeutics.
ClearB Therapeutics Tech Stack
A closer look at the technologies used by ClearB Therapeutics
ClearB Therapeutics News & Media
ClearB Therapeutics Announces License and Collaboration With Adjuvance Technologies to Access a Novel Saponin Adjuvant, TQL-1055, and Upcoming Poster Presentations of Pre-Clinical Chronic Hepatitis B Data at AASLD 2024
CONCORD, Mass.--(BUSINESS WIRE)--ClearB Therapeutics, Inc., a company developing therapeutic vaccines designed to drive a functional cure for Hepatitis B, announced today that the company has licensed TQL-1055 from Adjuvance Technologies, Inc. TQL-1055 is a novel saponin-based adjuvant that will be combined with ClearB’s proprietary variants of HBsAg, CLB-405 and CLB-505. Pre-clinical data related to this therapeutic vaccine combination will be presented as posters at the American Association fClearB Therapeutics Announces Upcoming Poster Presentations of Pre-Clinical Chronic Hepatitis B Data at EASL 2024
CONCORD, Mass.--(BUSINESS WIRE)--ClearB Therapeutics, Inc., a company developing CLB-3000, a therapeutic vaccine designed to drive a functional cure for Hepatitis B, announced today that two abstracts will be presented as posters at the European Association for the Study of the Liver (EASL) International Liver Congress (ILC) 2024, taking place in Milan, Italy 5 – 8 June 2024. In addition, one of the posters has been selected as a TOP presentation (see details below). “While weClearB Therapeutics Announces First Patient Dosed in a Phase 1b
CONCORD, Mass.--(BUSINESS WIRE)--ClearB Therapeutics, Inc., now a clinical-stage biotechnology company committed to developing therapies to drive functional cure in patients with chronic hepatitis B (CHB) infection, announced that the first patient has been dosed in the Phase 1b clinical study evaluating the therapeutic vaccine CLB-3000 (ACTRN1263000841673). Satisfactory review of safety data for this patient supported opening enrollment for the remainder of the cohort. CLB-3000 is a bivalent sClearB Therapeutics Announces Upcoming Poster Presentations of Pre-Clinical Chronic Hepatitis B Data at EASL 2023
CONCORD, Mass.--(BUSINESS WIRE)--ClearB Therapeutics, Inc., a company developing CLB-3000, a therapeutic vaccine designed to drive functional cure of hepatitis B, announced today that two abstracts were accepted for poster presentation at the European Association for the Study of the Liver (EASL) International Liver Congress (ILC) 2023, taking place in Vienna, Austria June 21 - 24, 2023. “As we continue to progress our therapeutic vaccine candidate, CLB-3000, toward first in human trials, we ar
Read more news
Top Blood & Organ Banks Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding ClearB Therapeutics
Sign Up For FreeTo access detailed company insights
ClearB Therapeutics is focused on developing a therapeutic vaccine aimed at redirecting the immune system of patients to achieve a functional cure for hepatitis B. The company addresses the unmet medical need for effective treatments in this area. Their innovative approach is currently being evaluated through clinical trials. ClearB Therapeutics ta... Read More
